PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
16972993-12	2006	In Group B (tamoxifen 10 mg/day), the mean percentage of nuclei stained by Ki-67 (MIB-1) was 24.69% before and 10.43% after tamoxifen treatment.	Tamoxifen	12-21	MIB E3 ubiquitin protein ligase 1	Homo sapiens	82-87	
16972993-16	2006	Tamoxifen significantly reduced monoclonal antibody Ki-67 (MIB-1), estrogen receptor (1D5) and progesterone receptor positivity (PgR 636) in the breast epithelium of carcinoma patients treated with a 10 mg dose of tamoxifen for 14 days.	Tamoxifen	0-9	MIB E3 ubiquitin protein ligase 1	Homo sapiens	59-64	
12101196-3	2002	RESULTS: In benign endometrium the mean MIB-1 index in the epithelium was higher in tamoxifen users than in non-users (mean, 13% (SD, 13%) v mean, 2% (SD, 2%); p < 0.05), whereas in endometrial cancer the MIB-1 index was higher, but similar in tamoxifen users and non-users (mean, 32% (SD, 24%) and mean, 35% (SD, 18%)).	Tamoxifen	84-93	MIB E3 ubiquitin protein ligase 1	Homo sapiens	40-45	
12101196-3	2002	RESULTS: In benign endometrium the mean MIB-1 index in the epithelium was higher in tamoxifen users than in non-users (mean, 13% (SD, 13%) v mean, 2% (SD, 2%); p < 0.05), whereas in endometrial cancer the MIB-1 index was higher, but similar in tamoxifen users and non-users (mean, 32% (SD, 24%) and mean, 35% (SD, 18%)).	Tamoxifen	84-93	MIB E3 ubiquitin protein ligase 1	Homo sapiens	208-213	
12101196-3	2002	RESULTS: In benign endometrium the mean MIB-1 index in the epithelium was higher in tamoxifen users than in non-users (mean, 13% (SD, 13%) v mean, 2% (SD, 2%); p < 0.05), whereas in endometrial cancer the MIB-1 index was higher, but similar in tamoxifen users and non-users (mean, 32% (SD, 24%) and mean, 35% (SD, 18%)).	Tamoxifen	247-256	MIB E3 ubiquitin protein ligase 1	Homo sapiens	40-45	
12101196-6	2002	CONCLUSION: The proliferation index (as measured by MIB-1) in benign endometrial epithelium is higher in tamoxifen users than in non-users, and this might play a role in the reported higher incidence of endometrial cancer in postmenopausal tamoxifen users.	Tamoxifen	105-114	MIB E3 ubiquitin protein ligase 1	Homo sapiens	52-57	
12101196-6	2002	CONCLUSION: The proliferation index (as measured by MIB-1) in benign endometrial epithelium is higher in tamoxifen users than in non-users, and this might play a role in the reported higher incidence of endometrial cancer in postmenopausal tamoxifen users.	Tamoxifen	240-249	MIB E3 ubiquitin protein ligase 1	Homo sapiens	52-57	
11843850-1	2001	The purpose of this study was to study the monoclonal antibody MIB-1 in the normal breast epithelium adjacent to a fibroadenoma in women in the luteal phase of the menstrual cycle who were treated with tamoxifen at doses of 10 and 20 mg for 22 days.	Tamoxifen	202-211	MIB E3 ubiquitin protein ligase 1	Homo sapiens	63-68	
11843850-7	2001	The mean percentage of stained nuclei per 1,000 cells was 9.2 in group A, 4.5 in group B, and 3.2 in group C. The Fisher"s test revealed that tamoxifen significantly reduced MIB-1 at doses of 10 and 20 mg compared with the placebo group (p < 0.0001), with no significant differences between doses in terms of proliferative activity (p=0.21).	Tamoxifen	142-151	MIB E3 ubiquitin protein ligase 1	Homo sapiens	174-179	
11261829-0	2001	Change in expression of ER, bcl-2 and MIB1 on primary tamoxifen and relation to response in ER positive breast cancer.	Tamoxifen	54-63	MIB E3 ubiquitin protein ligase 1	Homo sapiens	38-42	
11012741-5	2000	The proliferative activity within the adenomyosis, as determined by MIB1 staining, was higher in the tamoxifen group.	Tamoxifen	101-110	MIB E3 ubiquitin protein ligase 1	Homo sapiens	68-72